| abstract |
The invention features a therapy for the treatment of HCV without interferon and ribavirin. Preferably, the treatment lasts for a shorter treatment period, such as no more than 12 weeks. In one aspect, the treatment comprises administering to the individual infected with HCV at least two direct acting antiviral agents in the absence of interferon and ribavirin, wherein the treatment lasts for 12 weeks and the at least two The direct acting antiviral agent comprises (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. |